Zevtera / Mabelio (ceftobiprole)

Indicaton

Hospital- and community-acquired pneumonia

Therapeutic indications

Infectious disease

Type of product

Small molecule

Table

Phase

Marketed
Partnering status

Partnered
Partner

Advanz for Europe (excl. Nordics) and Israel; Unimedic for Nordics; Hikma for MENA region, Knight Grupo Biotoscana for Latin America; Avir for Canada, CR Gosun for China, JSC Lancet for Eurasian Economic Union
Available in

Major European and several international markets

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

Cadazolid

Crohn's disease

Phase II started

Zevtera / Mabelio (ceftobiprole)

Staphylococcus aureus bacteremia

Phase III completed